Proteome Heterogeneity in Colorectal Cancer

Lim, Lay Cheng; Lim, Yang Mooi

doi:10.1002/pmic.201700169

Cited by 18 publications

(20 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, right-and left-sided CRC also have distinct mutational profiles [17]. Studies have also found significant differences in protein expression and plasma metabolites between patients with tumors in the right or left colon [18][19][20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

N-glycomic profiling of colorectal cancer according to tumor stage and location

et al. 2020

View full text Add to dashboard Cite

Alterations in glycosylation are seen in many types of cancer, including colorectal cancer (CRC). Glycans, the sugar moieties of glycoconjugates, are involved in many important functions relevant to cancer and can be of value as biomarkers. In this study, we have used mass spectrometry to analyze the N-glycan profiles of 35 CRC tissue samples and 10 healthy tissue samples from non-CRC patients who underwent operations for other reasons. The tumor samples were divided into groups depending on tumor location (right or left colon) and stage (II or III), while the healthy samples were divided into right or left colon. The levels of neutral and acidic N-glycan compositions and glycan classes were analyzed in a total of ten different groups. Surprisingly, there were no significant differences in glycan levels when all right-and left-sided CRC samples were compared, and few differences (such as in the abundance of the neutral N-glycan H3N5) were seen when the samples were divided according to both location and stage. Multiple significant differences were found in the levels of glycans and glycan classes when stage II and III samples were compared, and these glycans could be of value as candidates for new markers of cancer progression. In order to validate our findings, we analyzed healthy tissue samples from the right and left colon and found no significant differences in the levels of any of the glycans analyzed, confirming that our findings when comparing CRC samples from the right and left colon are not due to normal variations in the levels of glycans between the healthy right and left colon. Additionally, the levels of the acidic glycans H4N3F1P1, H5N4F1P1, and S1H5N4F1 were found to change in a cancer-specific but colon location-nonspecific manner, indicating that CRC affects glycan levels in similar ways regardless of tumor location.

show abstract

Section: Introductionmentioning

confidence: 99%

N-glycomic profiling of colorectal cancer according to tumor stage and location

et al. 2020

View full text Add to dashboard Cite

show abstract

“…3 CRC has been reported to be prevalent in the elderly with an average age of about 71 years old; however, the average age of CRC has been falling in recent years; so the incidence of the disease in people under 50 years are afflicted. 5 To our relief, microRNAs (miRs) have been proven to be successful tumor suppressors in the treatment of various types of carcinomas as they can function in inhibiting tumor or oncogenes. 5 To our relief, microRNAs (miRs) have been proven to be successful tumor suppressors in the treatment of various types of carcinomas as they can function in inhibiting tumor or oncogenes.…”

mentioning

confidence: 99%

Overexpression of microRNA‐98 inhibits cell proliferation and promotes cell apoptosis via claudin‐1 in human colorectal carcinoma

Zheng

Luo

Gan

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Colorectal carcinoma (CRC) is a major cause of cancer‐related deaths worldwide, and investigations on novel targets are imperative. MiR‐98 has been reported to act as a tumor suppressor in several cancers. To evaluate miR‐98 as a novel anticancer molecule for CRC, examinations to validate whether miR‐98 conferred an inhibiting effect on proliferation, migration, and invasion were performed. The microarray‐based gene expression profiling involving CRC was used to identify the differentially expressed genes. The potential relationship between miR‐98 and CLDN1 was analyzed by cell experimentation. Then, the CRC cells were transfected with miR‐98 mimic or miR‐98 inhibitor to investigate the potential effect of miR‐98 overexpression and depletion on CRC cell proliferation, migration, invasion, and apoptosis. The expressions of CLDN1, Bcl‐2 associated protein x (Bax), runt‐related transcription factor 3 (RUNX3), B‐cell lymphoma 2 (Bcl‐2), C‐myc, and proliferating cell nuclear antigen (PCNA) were determined. The downregulated miR‐98 along with an upregulated CLDN1 was observed in CRC, in which miR‐98 could target to regulate CLDN1. The overexpression of miR‐98 or silencing of CLDN1 was shown to increase the expression of Bax and RUNX3 along with promoted cell apoptosis and arrested cells in G1 phase, while decreasing the expression of CLDN1, Bcl‐2, C‐myc, and PCNA with suppressed proliferation, migration, and invasion. Collectively, the current study supports the notion that miR‐98 plays an inhibitory role in human CRC cell proliferation, migration, and invasion and act as a contributor for cell apoptosis by downregulating CLDN1. The current study highlights a potential future strategy to help prevent the development of CRC.

show abstract

“…We found no protein shared between all secretome and proteome studies. This discrepancy may be due to the diversity of proteomic techniques used by different studies; or limitations in proteomic analysis related to sample preparation and sample heterogeneity, proteome complexity to be analyzed, especially regarding protein expression levels; and limitations of the analytical methods [112][113][114][115]. To overcome these limitations, we selected the proteins presented in two or more studies, aiming to increase the possibility of detecting proteins involved in pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Cancers 2020, 12, x 14 of 32 determined by Cox univariate regression analysis is shown in each Kaplan-Meier survival plot. Datasets of PDAC patients: PDAC-TCGA [112], PACA-AU-ICGC [113], GSE21501 [19], and GSE28735 [20,114].…”

Section: Secretome Gene Expression Predicts Cancer Outcomes In Differmentioning

confidence: 99%